ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1040 • ACR Convergence 2024

    Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics

    Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Cathy Lee Ching9, Zineb Aouhab10, Swamy Venuturupalli11, Daniel Wallace12, rosalind Ramsey-Goldman13, Alfred Kim14, Maureen McMahon15, S. Sam Lim16, Kalpana Bhairavarasu17, Alexa Meara18 and Kenneth Kalunian19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9UMMC, Jackson, MS, 10Loyola University Medical Center, Oak Brook, IL, 11Attune Health, Beverly Hills, CA, 12Cedars Sinai Medical Center, Studio City, CA, 13Northwestern University, Chicago, IL, 14Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 15UCLA David Geffen School of Medicine, Los Angeles, CA, 16Emory University, Atlanta, GA, 17Baylor College of Medicine, Sugar Land, TX, 18The Ohio State University Wexner Medical Center, COLUMBUS, OH, 19University of California San Diego, La Jolla, CA

    Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
  • Abstract Number: 1102 • ACR Convergence 2024

    Risk of Mortality and Major Cardiovascular-Kidney Outcomes in Patients with Tophaceous versus Non-Tophaceous Gout

    Gregory Challener1, kevin sheng-kai ma1, Natalie McCormick1, Chio Yokose2, Alex Tinianow1 and Hyon K. Choi3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Massachusetts General Hospital, Lexington, MA

    Background/Purpose: While it is well established that patients with gout have increased mortality risk compared to the general population [1, 2, 3], it is less…
  • Abstract Number: 1109 • ACR Convergence 2024

    Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women

    Laura Scagnellato1, Antonio Collesei2, Sonia farah3, Carlomaurizio Montecucco4, Francesca Oliviero5, Bernd raffeiner6, Marta favero5, Amelia Damasco5, doria Andrea5, Fausto Salaffi3 and Roberta Ramonda7, and SIR Study Group on Crystal Arthropaties, 1Rheumatology Unit, University of Padova, Padova, Italy, 2IRCCS Istituto Oncologico Veneto IOV, Padova, Italy, 3Polytechnic University of Marche, Jesi (AN), Italy, 4IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 5University of Padova, Padova, Italy, 6General Hospital of Bolzano, Bolzano, Italy, 7Rheumatology Unit, University of Padova, Italy, Padova, Italy

    Background/Purpose: Crystal arthropaties, including gout and calcium pyrophosphate deposition disease (CPPD), are prevalent and burdensome conditions. The ALLSTAR model allows the identification of reliable causal,…
  • Abstract Number: 1125 • ACR Convergence 2024

    Non-Classical Complications of Adult-Onset Still’s Disease: A Multicenter Spanish Study

    Javier Narvaez-García1, Maria Jesus García de Yebenes2, Susana Holgado3, Alejandro Olive4, Ivette Casafont-Sole3, Santos Castañeda5, Cristina Valero6, María Martín López7, Patricia Carreira8, Maribel Mora Limiñana9, Laura Nuño10, Angel Robles Marhuenda11, Pilar Bernabéu12, J Campos Esteban13, Genaro Graña14, Vera Ortiz15, Marisol Camacho16, Carmen Vargas17, Judith Sanchez-Manubens18 and Jordi Anton19, 1Hospital Universitario de Bellvitge, Barcelona, Spain, 2Instituto de Salud Musculoesquelética, Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Hospital de la Princesa, Madrid, Spain, 7General University Hospital of Ciudad Real, Ciudad de México, Spain, 8Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 9Parc Sanitari Sant Joan de Deu, Sant Boi, Barcelona, Spain, 10Hospital Universitario La Paz, Madrid, Spain, 11Hospital Universitario La Paz, Madrid, Madrid, Spain, 12Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, 13Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 14Complejo Hospitalario Universitario de A Coruña, La Coruña, Spain, 15Hospital General de Granollers, Barcelona, Spain, 16Hospital Universitario Virgen del Rocío, Sevilla, Spain, 17Hospital Universitario Virgen Macarena, Sevilla, Spain, 18Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain, 19Hospital Sant Joan de Déu, Barcelona, Spain

    Background/Purpose: Adult-onset Still's disease (AOSD) is a rare systemic disorder characterized typically by fever, arthritis, skin rash, leukocytosis, and hyperferritinemia, which are the hallmarks of…
  • Abstract Number: 1106 • ACR Convergence 2024

    Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients

    Adrián Martín-Gutiérrez1, Javier Loricera2, Carmen Secada Gómez3, Clara Moriano4, Javier Narvaez-García5, Vicente Aldasoro6, Olga Maíz Alonso7, Iñigo Hernández-Rodríguez8, Paloma Vela-Casasempere9, Susana Romero Yuste10, Eugenio De Miguel11, Eva Galindez-Agirregoikoa12, Jesus C. Fernandez-López13, ivan Ferraz-Amaro14, Julio Sánchez-Martín15, José Luis Callejas16, Patricia Moya Albarado17, Cristina Campos Fernández18, Fernando Lopez-Gutierrez19, Santos Castañeda20 and Ricardo Blanco-Alonso21, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital León, LEON, Spain, 5Hospital Universitario de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Navarra, Pamplona, Spain, 73Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, 8Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 9Hospital General Universitario Alicante, Alicante, Spain, 10Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 11Hospital Universitario La Paz, Madrid, Spain, 12BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 1311Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, 14Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 15Hospital Universitario 12 de Octubre, Madrid, Spain, 16Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 17Hospital de San Pau, Barcelona, Spain, 18Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, 19Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 20Hospital Universitario de la Princesa, Madrid, Spain, 21Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
  • Abstract Number: 1093 • ACR Convergence 2024

    Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias

    Joshua Baker1, Lindsay Helget2, chung-Chou Chang3, Bryant England2, Brian Coburn1, Harlan Sayles2, Punyasha Roul4 and Ted Mikuls2, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3University of Pittsburgh, Pittsburgh, PA, 4UNMC, Omaha, NE

    Background/Purpose: Prior studies reported a lower risk of dementia among patients with gout suggesting that hyperuricemia might play a neuroprotective role. However, risk estimates for…
  • Abstract Number: 1104 • ACR Convergence 2024

    Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era

    Carmen Lasa Teja1, Amparo Sánchez-López2, María Enriqueta Peiró3, Mónica Renuncio-García4, Adrián Martín-Gutiérrez5, Carmen Secada Gómez6, Juan Irure-Ventura7, Marcos Lopez-Hoyos8 and Ricardo Blanco-Alonso9, 1Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, Immunology, Santander, Spain, 5Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 6Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 7Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Cantabria, Spain, 8Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, 9Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: There have been increasing reports of cutaneous manifestations during COVID‐19 pandemic. An increase in awareness by physicians made them to increase the number of…
  • Abstract Number: 1120 • ACR Convergence 2024

    Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra

    Zeynep Toker Dincer1, Damla Raimoglu2, Erkin Yilmaz3, Ayten Dag1, Sejla Karup4, Melike Melikoglu1 and Serdal Ugurlu5, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Cardiology, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey, 4Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Idiopathic recurrent pericarditis (IRP) is characterized by recurrent pericarditis attacks, and autoinflammatory pattern has been highlighted due to similarities in both clinical features and…
  • Abstract Number: 1129 • ACR Convergence 2024

    Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever

    Admir Öztürk1, Murad Kucur2, Lara Yagci1 and Serdal Ugurlu3, 1Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Engineering Faculty, Mechanical Engineering Department, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease caused by mutations in the MEFV gene. Colchicine is the first-line treatment of FMF. Although…
  • Abstract Number: 1116 • ACR Convergence 2024

    Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry

    Shivang Chaudhary1, Kaushik Gokul1, Kishan Patel2, Simran Bhimani3, Yash Deshpande3, Adam Kilian1, Ravi Nayak1, Deana Mikhalkova1 and Chaitanya Rojulpote1, 1Saint Louis University, St. Louis, MO, 2Riverside Community Hospital, Riverside, CA, 3The Wright Center for graduate medical education, Scranton, PA

    Background/Purpose: Sarcoidosis is a complex, multisystemic disorder predominantly affecting the pulmonary system but can also involve extra-pulmonary organs such as the heart. Mortality in sarcoidosis…
  • Abstract Number: 1031 • ACR Convergence 2024

    Access to Advanced Therapies in Axial Spondyloarthritis in Latin America, Data from the PANLAR-ESPALDA Registry

    Rodrigo Garcia Salinas1, Fernando Andres Sommerfleck2, Diego Vila3, Daniel Palleiro4, Daniel Fernández-Ávila5, Julio César Casasola Vargas6, Maria Amada Barcia7, Dora Liliana Candia Zuniga8, Nicolas Martin Marin Zucaro9, María Lorena Brance10 and Wilson Bautista-Molano11, 1Hospital Italiano La Plata, La Plata, Argentina, 2Sanatorio Julio Mendez, Buenos Aires, Argentina, 3Hospital Virgen del Carmen, Campana, Buenos Aires, Argentina, 4Instituto Nacional de Reumatologia, Montevideo, Uruguay, 55Hospital San Ignacio, Colombia, BOGOTA, Colombia, 6Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, 77Hospital General Portoviejo del Instituto Ecuatoriano de Seguridad Social (IESS), Guayaquil, Ecuador, 88Hospital Regional Primero de Octubre ISSTE, Fuerzas Armadas, Mexico City, Mexico, 9Hospital Italiano de Buenos Aires, Capital Federal, Argentina, 10School of Medicine, Rosario National University, Argentina, Rosario, Argentina, 11University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia

    Background/Purpose: Access to advanced treatments in LATAM poses challenges due to various socioeconomic factors. The PANLAR-ESPALDA registry was established with the objective of gathering data…
  • Abstract Number: 1068 • ACR Convergence 2024

    Improving Health Numeracy Literacy in Pediatric Patients with SLE

    Nicole Salach1, Sarah Rogal1, Jessica Simpson1, Sangeeta Sule2, Abigail Bosk3 and Catherine Park1, 1Children's National Hospital, Washington DC, DC, 2Children's National Hospital, Washington, DC, 3Children's National Hospital, Bethesda, DC

    Background/Purpose: Health literacy is key to better patient outcomes. One aspect of health literacy that warrants additional investigation in patients who have systemic lupus erythematosus…
  • Abstract Number: 1130 • ACR Convergence 2024

    Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease

    Melanie Hagen1, Laura Bucci1, Sebastian Boeltz2, Danae-Mona Noethling2, Tobias Rothe2, Maria Gabriella Raimondo1, Carlo Tur1, Andreas Wirsching1, Jochen Wacker1, Aline Bozec1, Georg Schett3 and Ricardo Grieshaber-Bouyer1, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
  • Abstract Number: 1139 • ACR Convergence 2024

    Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes

    Shinji Izuka1, Toshihiko Komai2, Hayato Yuuki2, Ikuko Ueda3, Manabu Fujimoto4, Hiroyuki Fukui5, Masaru Takeshita6, Natsuka Umezawa7, Shinsuke Yasuda7, Mitsutaka Yasuda8, Yuichiro Fujieda9, Tatsuya Atsumi9, Takeshi Iwasaki10, Akio Morinobu10, Yuya Kondo11, Isao Matsumoto11, Toshio Kawamoto12, Masakazu Matsushita12, Naoto Tamura13, Taro Iwamoto14, Hiroshi Nakajima14, Ken Yoshida15, Takeo Isozaki16, Nobuyuki Yajima16, Keiichi Sakurai17, Kimito Kawahata17, Yasuyuki Kamata18, Kojiro Sato18, Yoshiya Tanaka19, Akari Suzuki20, Kazuhiko Yamamoto21, Tomohisa Okamura22 and Keishi Fujio2, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, 3Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, 4Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, 6Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 7Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, 9Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 10Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, 11Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, 12Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, 13Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 14Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, 15Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, 16Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, 17Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, 18Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, 19Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 20Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, 21Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, 22Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
  • Abstract Number: 1127 • ACR Convergence 2024

    Risk of Ocular Inflammatory Conditions in Patients with Autoimmune Diseases: A Retrospective Study Using the National Inpatient Sample

    Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

    Background/Purpose: Autoimmune diseases are known to cause various ocular inflammatory conditions and are often the initial presentation in many of these diseases. This study aims…
  • « Previous Page
  • 1
  • …
  • 170
  • 171
  • 172
  • 173
  • 174
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology